Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

413.81USD
1 Apr 2015
Change (% chg)

$-8.43 (-2.00%)
Prev Close
$422.24
Open
$423.20
Day's High
$423.32
Day's Low
$407.55
Volume
949,722
Avg. Vol
644,008
52-wk High
$480.13
52-wk Low
$272.02

BIIB.OQ

Chart for BIIB.OQ

About

Biogen Inc., formerly Biogen Idec Inc., is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. AVONEX is prescribed... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $99,063.62
Shares Outstanding(Mil.): 234.61
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 34.10 40.70 41.18
EPS (TTM): 12.38 -- --
ROI: 26.64 16.89 16.23
ROE: 30.21 17.42 17.07
Search Stocks

Exclusive: Biogen shortens name, expands ambitions in Alzheimer's, ALS

NEW YORK - Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights. | Video

23 Mar 2015

Biogen's Alzheimer's drug slows mental decline in early study

- An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. | Video

20 Mar 2015

UPDATE 1-Biogen's Alzheimer's drug slows mental decline in early study

March 20 - An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment.

20 Mar 2015

US STOCKS-Wall St set for higher open as Nike provides lift

* Futures up: Dow 148 pts, S&P 15 pts, Nasdaq 36 pts (Adds quote, updates prices)

20 Mar 2015

UPDATE 1-Dementia drug research aided by $100 mln venture capital fund

* Backers include British govt, GSK, J&J, Pfizer, Lilly, Biogen

17 Mar 2015

Biogen forecasts 2015 earnings well ahead of Street view

- Biogen Idec Inc on Thursday reported fourth-quarter profit and issued a 2015 earnings forecast that both sailed past Wall Street estimates, driven by strong sales of its oral multiple sclerosis drug Tecfidera, sending shares more than 7 percent higher.

29 Jan 2015

Biogen forecasts 2015 earnings well ahead of Street view

Jan 29 - Biogen Idec Inc on Thursday reported higher-than-expected fourth-quarter profit on strong demand for its oral multiple sclerosis drug Tecfidera and issued a forecast for 2015 earnings far higher than Wall Street forecasts.

29 Jan 2015

Biogen to buy private U.K. company with chronic pain drug

- Biogen Idec Inc on Sunday said it would buy small, privately-held Convergence Pharmaceuticals to acquire the U.K.-based company's portfolio of experimental drugs for chronic nerve pain.

11 Jan 2015

Biogen to buy private U.K. company with chronic pain drug

Jan 11 - Biogen Idec Inc on Sunday said it would buy small, privately-held Convergence Pharmaceuticals to acquire the U.K.-based company's portfolio of experimental drugs for chronic nerve pain.

11 Jan 2015

Biogen shares fall after optic nerve study results seen as mixed

- Biogen Idec Inc said an experimental drug showed evidence of biological repair of the optic nerve in patients with acute inflammation of the optic nerve, but shares fell as analysts wondered how promising the mid-stage study results were.

08 Jan 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks